Main Article Content
Teratogens, pregnancy, pharmacists, drug information
We report on the first Helpline for pharmacists dealing with the safety of medications in pregnancy and during breastfeeding. Pharmacists from all parts of Canada participated in this pilot, receiving guidance in approximately 90% of cases. There were 472 inquiries relating to 598 products with regards to safety in pregnancy and 197 calls relating to 249 products regarding exposure in breastfeeding. All callers who were surveyed found the service helpful in counseling both patients and physicians.
2. Pellerin P, Elefant E. Medication and pregnancy counseling, an incomfortable role for the retail pharmacists (article in French). Ann Pharm Fr 2004;62(11):253-9.
3. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 2001;95(1):127–31.
4. Pichereau J, Pathak A, Lacroix I, Montastruc JL, Damase-Michel C. Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. 27th French pharmacovigilance meeting, Montpellier. 10-12 April 2006. Fundamental Clin Pharmacol 2006;20:178 [Abstract 203].
5. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160(5 Pt 1):1190-4.
6. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical, and radiation exposure during the first trimester. Teratology 1990;41(6):657-61.
7. De Santis M, Straface G, Cavaliere AF, Cinque B, Carducci B, Caruso A. Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol 2006:58(2):91-9.
8. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: Evaluation of perception risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health 2005;8(4):214-20.
9. Moretti ME, Koren G. Motherisk: The Toronto model for counseling in reproductive toxicology. In: Koren G, ed. Maternal-fetal toxicology - A clinician’s guide. 3rd ed. Marcel Dekker, Inc. NY; 2001: 767-88.
10. Briggs, GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Lippincott Williams & Wilkins, Philadelphia, PA; 2008.
11. Micromedex 1.0 Healthcare Series. Website. http://www.thomsonhc.com.myaccess.library.ut oronto.ca/hcs/librarian/ND_T/HCS/CS/DE3D62 /ND_PR/Main/DUPLICATIONSHIELDSYNC/ 8144E6/ND_PG/PRIH/ND_B/HCS/ND_P/Main /PFActionId/hcs.Home Accessed July 2010.
12. Hale TW. Medications and mothers’ milk. A manual of lactational pharmacology. 13th ed. Hale Publishing, L.P. Amarillo, TX; 2008.
13. Garriguet D. Medication use among pregnant women. Health Rep 2006;17:9-18.
14. Irvine L, Flynn RWV, Libby G, et al. Drugs dispensed in primary care during pregnancy. A record-linkage analysis in Tayside, Scotland. Drug Saf 2010;33:593-604.
15. Wen SW, Yang T, Krewski D, et al. Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population. J Perinatol 2008;28:324-9.
16. Gagne JJ, Maio V, Berghella V, et al. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Parmacol 2008;64:1125-32.
17. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006;15:537-45.
18. The Pharmacy Group. The Community Pharmacy 2010. The complete report on trends and insights in Canada. Rogers Publishing Ltd. Toronto; 2010.
19. Shoppers DrugMart. Drug Store Network- As of October 9, 2010. http://www.shoppersdrugmart.ca/english/corporate _information/investor_relations/corporate_overvie w/store_network/index.html Accessed on November 15, 2010.
20. Statistics Canada. Population and dwelling counts for Canada, provinces and territories 2006 and 2001 censuses. 2006. http://www12.statcan.ca/censusrecensement/ 2006/dp-pd/hlt/97- 550/Index.cfm?TPL=P1C&Page=RETR&LAN G=Eng&T=101 Accessed on March 3, 2010.
21. Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy. Drug Saf 2000; 23:245-53.
22. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-943.
23. Koren G, Sakaguchi S, Klieger C, et al. Toward improved pregnancy labeling. J Popul Ther Clin Pharmacol 2010;17:e349-57.